Renal Cancer - Results from #1040

Diagnostic Imaging in the Evaluation of Asymptomatic Microhematuria: Systematic Review and Meta-Analysis. March 10, 2023

Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma Patients. March 9, 2023

The effect of perioperative blood transfusion on survival after renal cell carcinoma nephrectomy: A systematic review and meta-analysis. March 9, 2023

The IRON Study: Investigation of Robot-assisted Versus Open Nephron-sparing Surgery. March 8, 2023

Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era. March 8, 2023

The Learning Curve for Radical Nephrectomy for Kidney Cancer: Implications for Surgical Training. March 8, 2023

Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab. March 7, 2023

Factors associated with clinical trial participation for patients with renal cell carcinoma. March 7, 2023

Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. March 6, 2023

Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. March 6, 2023

Comprehensive Management of Renal Masses in Solitary Kidneys. March 6, 2023

Trends of kidney cancer burden from 1990 to 2019 in European Union 15 + countries and World Health Organization regions. March 6, 2023

Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer March 3, 2023

The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. March 3, 2023

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. March 3, 2023

Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective-prospective cohort multicentre study. March 2, 2023

Initial experience of robot-assisted partial nephrectomy with Hugo™ RAS system: implications for surgical setting. March 2, 2023

Plasma and Urine Free Glycosaminoglycans as Monitoring and Predictive Biomarkers in Metastatic Renal Cell Carcinoma: A Prospective Cohort Study. March 1, 2023

Construction of a prognostic prediction model for renal clear cell carcinoma combining clinical traits. March 1, 2023

A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. February 28, 2023

Page 53 of 456